These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 27230741)
1. HBM Mice Have Altered Bone Matrix Composition and Improved Material Toughness. Ross RD; Mashiatulla M; Acerbo AS; Almer JD; Miller LM; Johnson ML; Sumner DR Calcif Tissue Int; 2016 Oct; 99(4):384-95. PubMed ID: 27230741 [TBL] [Abstract][Full Text] [Related]
2. The high-bone-mass phenotype of novel transgenic mice with LRP5 A241T mutation. Wang X; Zhang H; Hu L; He J; Jiang Q; Ren L; Yu K; Fu M; Li Z; He Z; Zhu J; Wang Y; Jiang Z; Yang G Bone; 2024 Oct; 187():117172. PubMed ID: 38909879 [TBL] [Abstract][Full Text] [Related]
3. High Bone Mass-Causing Mutant LRP5 Receptors Are Resistant to Endogenous Inhibitors In Vivo. Niziolek PJ; MacDonald BT; Kedlaya R; Zhang M; Bellido T; He X; Warman ML; Robling AG J Bone Miner Res; 2015 Oct; 30(10):1822-30. PubMed ID: 25808845 [TBL] [Abstract][Full Text] [Related]
4. Gender specific LRP5 influences on trabecular bone structure and strength. Dubrow SA; Hruby PM; Akhter MP J Musculoskelet Neuronal Interact; 2007; 7(2):166-73. PubMed ID: 17627087 [TBL] [Abstract][Full Text] [Related]
5. Analysis of multiple bone responses to graded strains above functional levels, and to disuse, in mice in vivo show that the human Lrp5 G171V High Bone Mass mutation increases the osteogenic response to loading but that lack of Lrp5 activity reduces it. Saxon LK; Jackson BF; Sugiyama T; Lanyon LE; Price JS Bone; 2011 Aug; 49(2):184-93. PubMed ID: 21419885 [TBL] [Abstract][Full Text] [Related]
6. Bone mineral properties in growing Col1a2(+/G610C) mice, an animal model of osteogenesis imperfecta. Masci M; Wang M; Imbert L; Barnes AM; Spevak L; Lukashova L; Huang Y; Ma Y; Marini JC; Jacobsen CM; Warman ML; Boskey AL Bone; 2016 Jun; 87():120-9. PubMed ID: 27083399 [TBL] [Abstract][Full Text] [Related]
7. Induction of Lrp5 HBM-causing mutations in Cathepsin-K expressing cells alters bone metabolism. Kang KS; Hong JM; Horan DJ; Lim KE; Bullock WA; Bruzzaniti A; Hann S; Warman ML; Robling AG Bone; 2019 Mar; 120():166-175. PubMed ID: 30409757 [TBL] [Abstract][Full Text] [Related]
8. High bone mass in mice expressing a mutant LRP5 gene. Babij P; Zhao W; Small C; Kharode Y; Yaworsky PJ; Bouxsein ML; Reddy PS; Bodine PV; Robinson JA; Bhat B; Marzolf J; Moran RA; Bex F J Bone Miner Res; 2003 Jun; 18(6):960-74. PubMed ID: 12817748 [TBL] [Abstract][Full Text] [Related]
9. Bone biomechanical properties in LRP5 mutant mice. Akhter MP; Wells DJ; Short SJ; Cullen DM; Johnson ML; Haynatzki GR; Babij P; Allen KM; Yaworsky PJ; Bex F; Recker RR Bone; 2004 Jul; 35(1):162-9. PubMed ID: 15207752 [TBL] [Abstract][Full Text] [Related]
10. Intrinsic material properties of cortical bone. Lopez Franco GE; Blank RD; Akhter MP J Bone Miner Metab; 2011 Jan; 29(1):31-6. PubMed ID: 20503060 [TBL] [Abstract][Full Text] [Related]
11. Missense Mutations in LRP5 Associated with High Bone Mass Protect the Mouse Skeleton from Disuse- and Ovariectomy-Induced Osteopenia. Niziolek PJ; Bullock W; Warman ML; Robling AG PLoS One; 2015; 10(11):e0140775. PubMed ID: 26554834 [TBL] [Abstract][Full Text] [Related]
12. The LRP5 high-bone-mass mutation causes alveolar bone accrual with minor craniofacial alteration. Turkkahraman H; Flanagan S; Zhu T; Bellido TM; Yuan X J Periodontal Res; 2023 Aug; 58(4):723-732. PubMed ID: 37128744 [TBL] [Abstract][Full Text] [Related]
13. Fourier transform infrared imaging microspectroscopy and tissue-level mechanical testing reveal intraspecies variation in mouse bone mineral and matrix composition. Courtland HW; Nasser P; Goldstone AB; Spevak L; Boskey AL; Jepsen KJ Calcif Tissue Int; 2008 Nov; 83(5):342-53. PubMed ID: 18855037 [TBL] [Abstract][Full Text] [Related]
14. Are Changes in Composition in Response to Treatment of a Mouse Model of Osteogenesis Imperfecta Sex-dependent? Boskey AL; Marino J; Spevak L; Pleshko N; Doty S; Carter EM; Raggio CL Clin Orthop Relat Res; 2015 Aug; 473(8):2587-98. PubMed ID: 25903941 [TBL] [Abstract][Full Text] [Related]
15. DMP1 depletion decreases bone mineralization in vivo: an FTIR imaging analysis. Ling Y; Rios HF; Myers ER; Lu Y; Feng JQ; Boskey AL J Bone Miner Res; 2005 Dec; 20(12):2169-77. PubMed ID: 16294270 [TBL] [Abstract][Full Text] [Related]
16. Bone Matrix Composition Following PTH Treatment is Not Dependent on Sclerostin Status. Ross RD; Mashiatulla M; Robling AG; Miller LM; Sumner DR Calcif Tissue Int; 2016 Feb; 98(2):149-57. PubMed ID: 26514840 [TBL] [Abstract][Full Text] [Related]
17. Elevated circulating Sclerostin concentrations in individuals with high bone mass, with and without LRP5 mutations. Gregson CL; Poole KE; McCloskey EV; Duncan EL; Rittweger J; Fraser WD; Smith GD; Tobias JH J Clin Endocrinol Metab; 2014 Aug; 99(8):2897-907. PubMed ID: 24606091 [TBL] [Abstract][Full Text] [Related]
18. Novel familial mutation of LRP5 causing high bone mass: Genetic analysis, clinical presentation, and characterization of bone matrix mineralization. Roetzer KM; Uyanik G; Brehm A; Zwerina J; Zandieh S; Czech T; Roschger P; Misof BM; Klaushofer K Bone; 2018 Feb; 107():154-160. PubMed ID: 29208525 [TBL] [Abstract][Full Text] [Related]
19. The Effect of Overexpression of Lrp5 on the Temporomandibular Joint. Utreja A; Motevasel H; Bain C; Holland R; Robling A Cartilage; 2021 Dec; 13(2_suppl):419S-426S. PubMed ID: 33124433 [TBL] [Abstract][Full Text] [Related]
20. Clinical features, treatment, and follow-up of OPPG and high-bone-mass disorders: LRP5 is a key regulator of bone mass. Ren N; Lv S; Li X; Shao C; Wang Z; Mei Y; Yang W; Fu W; Hu Y; Sha L; Hu W; Zhang Z; Wang C Osteoporos Int; 2024 Aug; 35(8):1395-1406. PubMed ID: 38625381 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]